Letter to the Editor

Expression and Clinical Significance of CREPT and CDK4 in Cervical Cancer


No Abstract

1. Ramirez PT, Frumovitz M, Pareja R, et al (2018). Minimally invasive versus ab-dominal radical hysterectomy for cervical cancer. N Engl J Med, 379(20): 1895-1904.
2. Wang YM, Wang CJ, Fang FM, et al (2017). Differences in the outcomes and compli-cations between elderly and younger uter-ine cervical cancer patients treated by de-finitive radiotherapy - A propensity score-matched study. Gynecol Oncol, 145(2): 277-283.
3. Ma J, Ren Y, Zhang L, et al (2017). Knock-ing-down of CREPT prohibits the pro-gression of oral squamous cell carcinoma and suppresses cyclin D1 and c-Myc ex-pression. PLoS One, 12(4): e0174309.
4. Zhang H, Han R, Ling ZQ, et al (2018). PAQR4 has a tumorigenic effect in hu-man breast cancers in association with reduced CDK4 degradation. Carcinogenesis, 39(3): 439-446.
5. Patel S, Pancholi P, Visal T, et al (2017). Ab-stract 2172: ON 123300, an orally admin-istered novel CDK4/6 + ARK5 inhibi-tor, exhibits potent antitumor activity in vivo: comparative studies with Palbo-ciclib. Cancer Res, 77: 2172.
6. Vijayaraghavan S, Karakas C, Doostan I, et al (2017). CDK4/6 and autophagy inhibi-tors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun, 8: 15916.
7. Bollard J, Miguela V, de Galarreta MR, et al (2017). Palbociclib (PD-0332991), a selec-tive CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepato-cellular carcinoma. Gut, 66(7): 1286-1296.
IssueVol 50 No 2 (2021) QRcode
SectionLetter to the Editor
DOI https://doi.org/10.18502/ijph.v50i2.5365

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
YAO S, SUN H. Expression and Clinical Significance of CREPT and CDK4 in Cervical Cancer. Iran J Public Health. 50(2):418-420.